Calgent Biotechnology

Executive Summary

Calgent Biotechnology, headquartered in New Taipei City, Taiwan, is a private preclinical-stage biopharmaceutical company dedicated to developing innovative oncology and immunology therapeutics. Founded in 2019, the company leverages an integrated R&D platform spanning translational research, pharmacology, formulation, and clinical development to build a pipeline of new molecular entities and reformulated drugs. Its strategic approach combines proprietary programs with in-licensing to accelerate the delivery of precision medicines, particularly for age-related diseases and healthy aging. Despite being early-stage, Calgent’s focus on addressing unmet medical needs and its robust platform position it as a potential player in the precision medicine space.

Upcoming Catalysts (preview)

• Q3 2026Lead oncology program IND filing45% success
• Q2 2026Preclinical proof-of-concept data for immunology asset60% success
• Q4 2026Strategic partnership or in-licensing agreement50% success